{"id":7574,"date":"2024-07-18T16:02:13","date_gmt":"2024-07-18T15:02:13","guid":{"rendered":"https:\/\/els-solutions.com\/cms\/dev\/?p=7574"},"modified":"2024-07-18T16:02:13","modified_gmt":"2024-07-18T15:02:13","slug":"ema-recommends-10-new-drugs","status":"publish","type":"post","link":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/","title":{"rendered":"EMA proposes approval of 10 new drugs"},"content":{"rendered":"<\/p>\n<p style=\"text-align: center;\"><strong>EMA recommends approval of 10 new medicines<\/strong><\/p>\n<p style=\"text-align: center;\">The Committee for Medicinal Products for Human Use (CHMP) of the EMA (European Medicines Agency) recommended the approval of 10 medicines at its meeting in June 2024. These include Balversa (erdafitinib) for urothelial carcinoma and Eurneffy (epinephrine), the first nasal spray for allergic emergencies. <a href=\"https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024\" target=\"_blank\" rel=\"noopener\"><span class=\" author-d-iz88z86z86za0dz67zz78zz78zz74zz68zjz80zz71z9iz90z9z84zmz66zz71znz68znz69zz87z3z89zhz65zz89zybhz84zz79zkwtz79zsz76zdz122zjz80z7\">Read more here<\/span><\/a><\/p>\n<p style=\"text-align: center;\">If you need more information on regulatory issues, ELS can certainly help.<\/p>\n<p style=\"text-align: center;\"><span class=\" author-d-iz88z86z86za0dz67zz78zz78zz74zz68zjz80zz71z9iz90z9z84zmz66zz71znz68znz69zz87z3z89zhz65zz89zybhz84zz79zkwtz79zsz76zdz122zjz80z7\">Please do not hesitate to c<\/span>ontact your <a href=\"https:\/\/els-solutions.com\/onde-estamos\/\" target=\"_blank\" rel=\"noopener\">local ELS consultant<\/a>\u00a0or via email info@elssolutions.pt<\/p>\n<p>\n","protected":false},"excerpt":{"rendered":"<p>The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.<\/p>\n","protected":false},"author":9,"featured_media":7564,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[54,61],"tags":[62],"class_list":["post-7574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","category-news","tag-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EMA recommends approval of 10 new drugs<\/title>\n<meta name=\"description\" content=\"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA recommends approval of 10 new drugs\" \/>\n<meta property=\"og:description\" content=\"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"ELS Group - Accelerating Innovation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/els.solutions\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-18T15:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marketing ELS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing ELS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\"},\"author\":{\"name\":\"Marketing ELS\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\"},\"headline\":\"EMA proposes approval of 10 new drugs\",\"datePublished\":\"2024-07-18T15:02:13+00:00\",\"dateModified\":\"2024-07-18T15:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\"},\"wordCount\":808,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg\",\"keywords\":[\"News\"],\"articleSection\":[\"General\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\",\"url\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\",\"name\":\"EMA recommends approval of 10 new drugs\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg\",\"datePublished\":\"2024-07-18T15:02:13+00:00\",\"dateModified\":\"2024-07-18T15:02:13+00:00\",\"description\":\"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.\",\"breadcrumb\":{\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg\",\"width\":1200,\"height\":600,\"caption\":\"Medicamentos que s\u00e3o aprovados pela EMA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/els-solutions.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EMA proposes approval of 10 new drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/els-solutions.com\/en\/#website\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"name\":\"ELS Group - Accelerating Innovation\",\"description\":\"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica\",\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/els-solutions.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\",\"name\":\"ELS Group - Accelerating Innovation\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"width\":2226,\"height\":1080,\"caption\":\"ELS Group - Accelerating Innovation\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/els.solutions\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\",\"name\":\"Marketing ELS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"caption\":\"Marketing ELS\"},\"sameAs\":[\"https:\/\/els-solutions.com\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EMA recommends approval of 10 new drugs","description":"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/","og_locale":"en_US","og_type":"article","og_title":"EMA recommends approval of 10 new drugs","og_description":"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.","og_url":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/","og_site_name":"ELS Group - Accelerating Innovation","article_publisher":"https:\/\/www.facebook.com\/els.solutions\/","article_published_time":"2024-07-18T15:02:13+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg","type":"image\/jpeg"}],"author":"Marketing ELS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marketing ELS","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#article","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/"},"author":{"name":"Marketing ELS","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3"},"headline":"EMA proposes approval of 10 new drugs","datePublished":"2024-07-18T15:02:13+00:00","dateModified":"2024-07-18T15:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/"},"wordCount":808,"commentCount":0,"publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"image":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg","keywords":["News"],"articleSection":["General","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/","url":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/","name":"EMA recommends approval of 10 new drugs","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage"},"image":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg","datePublished":"2024-07-18T15:02:13+00:00","dateModified":"2024-07-18T15:02:13+00:00","description":"The EMA recommends the approval of 10 new drugs, highlighting Balversa and Eurneffy for emerging therapeutic innovations.","breadcrumb":{"@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#primaryimage","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/07\/ELS-Solutions-Meeting-highlights-from-the-Committee-1.jpg","width":1200,"height":600,"caption":"Medicamentos que s\u00e3o aprovados pela EMA"},{"@type":"BreadcrumbList","@id":"https:\/\/els-solutions.com\/en\/ema-recommends-10-new-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/els-solutions.com\/en\/"},{"@type":"ListItem","position":2,"name":"EMA proposes approval of 10 new drugs"}]},{"@type":"WebSite","@id":"https:\/\/els-solutions.com\/en\/#website","url":"https:\/\/els-solutions.com\/en\/","name":"ELS Group - Accelerating Innovation","description":"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/els-solutions.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/els-solutions.com\/en\/#organization","name":"ELS Group - Accelerating Innovation","url":"https:\/\/els-solutions.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","width":2226,"height":1080,"caption":"ELS Group - Accelerating Innovation"},"image":{"@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/els.solutions\/"]},{"@type":"Person","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3","name":"Marketing ELS","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","caption":"Marketing ELS"},"sameAs":["https:\/\/els-solutions.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/comments?post=7574"}],"version-history":[{"count":2,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7574\/revisions"}],"predecessor-version":[{"id":7585,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7574\/revisions\/7585"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media\/7564"}],"wp:attachment":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media?parent=7574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/categories?post=7574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/tags?post=7574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}